The full Senate is expected to vote on a FDA reform/user fee bill next week that closely resembles the version passed by the health committee, including the likely absence of a biogenerics measure, sources following the debate say. During last week's health committee mark up of S. 1082, many amendments were withdrawn with promises of compromise before floor debate, but committee leaders are reluctant to change much given that the committee comfortably passed the bill 15 to 6.